Drugs Likelihood of Approval
Uncover the likelihood of approval for pharmaceutical drugs currently in clinical pathways.
Access real-time data on how likely a specific drug will succeed at its current stage and ultimately be approved for commercialization.
Drugs are compared with comparable drugs in similar pathways, establishing key benchmarks for drugs of specific types. You’ll heighten your understanding of drug PTSR and LoA scores, and discover what contributes to successful approval.
Included in these reports:
- PTSR and LoA scores for specific drugs
- Score comparison to industry benchmarks
- Key factors contributing to a drug’s scores
We are the trusted, gold standard intelligence provider to the world’s largest industries
GlobalData powers faster, more informed decisions with:
- Granular industry intelligence: We develop deep, vertical-specific intelligence tailored to your industry, providing 360° insight.
- Exhaustive coverage: We synthesize our vast data universe into formats that support your decision-making needs, covering the sectors, themes, companies and geographies that matter to you.
- Proprietary datasets: We provide you with access to untapped pools of intelligence generated from our proprietary datasets and primary research capabilities.
- Robust methodologies: The quality and timeliness of our data is a key differentiator. We leverage robust research methodologies to turn millions of data points into trusted intelligence
Thousands of companies, government organizations, and decision makers rely on GlobalData
We have a track record of serving truly diverse clients, including:
- Corporates: From refining strategy to fostering innovation, our insights power decisions for all corporate functions.
- Investment firms: From balancing risks to identifying alpha signals, our insights are widely used by investors and financial analysts.
- Professional services: We give consultants, legal, and accounting firms the critical insights to make faster, more informed decisions.
- Other sectors: From media to academia, we work with sectors as diverse as our data.
The trusted, actionable and future-proof insight you need to stay ahead
We have decades of experience in being the gold standard intelligence provider based on:
- Unique data: Our proprietary data sources are unmatched and untapped, giving you exclusive insights to drive decisions.
- Expert analysis: Leverage collective expertise. Count on our extensive team of researchers, analysts, subject matter experts, and journalists, plus thousands of external thought-leaders.
- Real intelligence over AI: Experience a level of analysis that leaves AI in the dust. Unlock the proprietary datasets unseen by AI and gain a decisive edge.
- Time-saving research solutions: Save hundreds of hours on research. Our comprehensive reports let you focus on delivering actionable insights - not searching for them.
- Unparalleled global coverage: Tap into insights from anywhere. Our extensive global coverage offers an unrivalled view of the market landscape.
- One platform: Access all our unique data, expert analysis, and innovative solutions on one platform.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SYD-3521 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SYD-3521 in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SYD-3521 in Pancreatic Cancer Drug Details: SYD-3521 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SYD-3521 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SYD-3521 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SYD-3521 in Non-Small Cell Lung Cancer Drug Details: SYD-3521...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SYD-3521 in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SYD-3521 in Esophageal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SYD-3521 in Esophageal Cancer Drug Details: SYD-3521 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SYD-3521 in Papillary Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SYD-3521 in Papillary Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SYD-3521 in Papillary Renal Cell Carcinoma Drug Details: SYD-3521...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALG.APV-527 in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALG.APV-527 in Cervical Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALG.APV-527 in Cervical Cancer Drug Details: ALG.APV-527 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALG.APV-527 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALG.APV-527 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALG.APV-527 in Gastric Cancer Drug Details: ALG.APV-527 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALG.APV-527 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALG.APV-527 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALG.APV-527 in Solid Tumor Drug Details: ALG.APV-527 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALG.APV-527 in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALG.APV-527 in Endometrial Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALG.APV-527 in Endometrial Cancer Drug Details: ALG.APV-527 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALG.APV-527 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALG.APV-527 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALG.APV-527 in Non-Small Cell Lung Cancer Drug Details: ALG.APV-527...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALG.APV-527 in Throat Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALG.APV-527 in Throat Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALG.APV-527 in Throat Cancer Drug Details: ALG.APV-527 is under development for...